Satellos Bioscience Inc. - Asset Resilience Ratio
Satellos Bioscience Inc. (MSCL) has an Asset Resilience Ratio of 92.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Satellos Bioscience Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Satellos Bioscience Inc.'s Asset Resilience Ratio has changed over time. See MSCL net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Satellos Bioscience Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Satellos Bioscience Inc. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$19.30 Million | 51.47% |
| Short-term Investments | CA$15.31 Million | 40.82% |
| Total Liquid Assets | CA$34.61 Million | 92.30% |
Asset Resilience Insights
- Very High Liquidity: Satellos Bioscience Inc. maintains exceptional liquid asset reserves at 92.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Satellos Bioscience Inc. Industry Peers by Asset Resilience Ratio
Compare Satellos Bioscience Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Satellos Bioscience Inc. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Satellos Bioscience Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 71.58% | CA$52.27 Million ≈ $37.81 Million |
CA$73.02 Million ≈ $52.82 Million |
-4.20pp |
| 2023-12-31 | 75.78% | CA$33.57 Million ≈ $24.28 Million |
CA$44.30 Million ≈ $32.04 Million |
+53.21pp |
| 2022-12-31 | 22.57% | CA$1.40 Million ≈ $1.01 Million |
CA$6.20 Million ≈ $4.48 Million |
-- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more